SEC Form 4 · accession 0001237899-15-000014

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Michael S Aberman

Officer — SVP Strategy Investor Relation

Period of report

Feb 13, 2015

Accepted (ET)

Feb 18, 2015 · 4:40 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000872589

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 13, 2015	M	7,500	$24.00	A	26,100	D
Common Stock	Feb 13, 2015	F	447	$402.05	D	25,653	D
Common Stock	Feb 13, 2015	F	3,361	$402.05	D	22,292	D
Common Stock	Feb 17, 2015	S	100	$401.54	D	22,192	D
Common Stock^F2	Feb 17, 2015	S	300	$402.51	D	21,892	D
Common Stock^F3	Feb 17, 2015	S	600	$403.72	D	21,292	D
Common Stock^F4	Feb 17, 2015	S	1,692	$404.55	D	19,600	D
Common Stock^F5	Feb 17, 2015	S	900	$405.56	D	18,700	D
Common Stock	Feb 17, 2015	S	100	$406.24	D	18,600	D
Common Stock	holding	—	—		—	376	I	By 401(k) Plan

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F6	$24.00	Feb 13, 2015	M	7,500	D	—	Mar 22, 2020	Common Stock	7,500	21,668	D

Explanation of responses

F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2Represents volume-weighted average price of sales of 300 shares of Company stock on February 17, 2015 at prices ranging from $402.27 to $402.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 17, 2015 at each separate price.
F3Represents volume-weighted average price of sales of 600 shares of Company stock on February 17, 2015 at prices ranging from $403.24 to $403.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 17, 2015 at each separate price.
F4Represents volume-weighted average price of sales of 1,692 shares of Company stock on February 17, 2015 at prices ranging from $404.21 to $404.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 17, 2015 at each separate price.
F5Represents volume-weighted average price of sales of 900 shares of Company stock on February 17, 2015 at prices ranging from $405.09 to $405.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 17, 2015 at each separate price.
F6The stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.